The discovery of new drugs is essential for medical innovations, but the process is lengthy, high-risk, and expensive. This is due to manual research and analysis processes that are prone to human error and time-consuming workflows, raising the question as to whether AI could reduce these pitfalls.
Rather than bolting machine learning onto the existing drug discovery process, Isomorphic Labs is reimagining everything from first principles with an AI-first approach, leveraging machine learning to build predictive and generative models of biological phenomena to understand how novel drugs could perform. And the company differentiates itself from other AI-driven drug discovery startups by being a direct subsidiary of Alphabet, with access to resources, computing power, and partnerships with teams within DeepMind.
Now, the company is gearing up for its biggest leap yet - testing its AI-designed medicines on real people. After years of development, big-name partnerships, and a $600M funding round, Isomorphic says human clinical trials are finally within reach. In its London offices, scientists and AI are already teaming up to design potential treatments for diseases like cancer. The next step is putting those drugs to the test.
Kirsty
Company Specialist at Welcome to the Jungle